Citius Oncology, Inc. Research and Development Expense
Citius Oncology, Inc. (CTOR) reported Research and Development Expense of $218.50 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Citius Oncology, Inc. research and development expense for the quarter ending 2026-06-30 was $218.50K, a 76.71% decline year-over-year.
- Citius Oncology, Inc. research and development expense for the quarter ending 2026-03-31 was $1.08M, a 65.62% decline year-over-year.
- Citius Oncology, Inc. research and development expense for the quarter ending 2025-12-31 was $1.02M, a 19.47% decline year-over-year.
- Citius Oncology, Inc. research and development expense for the quarter ending 2025-09-30 was $1.08M, a 16.97% decline year-over-year.
- Citius Oncology, Inc. research and development expense for fiscal 2025 was $6.42M, a 30.32% increase from fiscal 2024.
- Citius Oncology, Inc. research and development expense for fiscal 2024 was $4.93M, a 16.14% increase from fiscal 2023.
- Citius Oncology, Inc. research and development expense for fiscal 2023 was $4.24M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $218.50K 10-Q · filed 2026-08-14 | $1.30M derived: sum of 2 quarters · filed 2026-08-14 | $2.32M 10-Q · filed 2026-08-14 | $3.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.08M 10-Q · filed 2026-05-15 | $2.10M 10-Q · filed 2026-05-15 | $3.17M derived: sum of 3 quarters · filed 2026-05-15 | $4.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.02M 10-Q · filed 2026-02-13 | $2.09M derived: sum of 2 quarters · filed 2026-02-13 | $3.03M derived: sum of 3 quarters · filed 2026-08-14 | $6.17M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $2.01M derived: sum of 2 quarters · filed 2026-08-14 | $5.15M derived: sum of 3 quarters · filed 2026-08-14 | $6.42M 10-K · filed 2025-12-23 |
| 2025-06-30 | $938.28K 10-Q · filed 2026-08-14 | $4.08M derived: sum of 2 quarters · filed 2026-08-14 | $5.34M 10-Q · filed 2026-08-14 | $6.64M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $3.14M 10-Q · filed 2026-05-15 | $4.40M 10-Q · filed 2026-05-15 | $5.70M derived: sum of 3 quarters · filed 2026-05-15 | $6.83M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.26M 10-Q · filed 2026-02-13 | $2.56M derived: sum of 2 quarters · filed 2026-02-13 | $3.69M derived: sum of 3 quarters · filed 2026-02-13 | $5.04M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $2.43M derived: sum of 2 quarters · filed 2025-12-23 | $3.78M derived: sum of 3 quarters · filed 2025-12-23 | $4.93M 10-K · filed 2025-12-23 |
| 2024-06-30 | $1.13M 10-Q · filed 2025-08-12 | $2.48M derived: sum of 2 quarters · filed 2025-08-12 | $3.63M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $1.35M 10-Q · filed 2025-05-14 | $2.50M 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $1.15M 10-Q · filed 2025-02-14 | |||
| 2023-09-30 | $4.24M 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |